Get started
Author

Giorgia Guaitoli

Observed names: G. Guaitoli, Guaitoli Giorgia, Guaitoli, Giorgia
Observed institutions: University of Modena and Reggio Emilia, Inserm, Université Paris-Saclay, Institut Gustave Roussy, Azienda Ospedaliero-Universitaria di Modena, Prédicteurs moléculaires et nouvelles cibles en oncologie
ORCID: 0000-0001-8671-9910
Observed ORCID: 0000-0001-8671-9910
OpenAlex ID: A5048627770
Differential influence of antibiotic therapy and other medications on oncological outcomes of patients with non-small cell lung cancer treated with first-line pembrolizumab versus cytotoxic chemotherapy
2021 · Alessio Cortellini, Massimo Di Maio, et al. · Journal for ImmunoTherapy of Cancer · 151
PDF
Dissecting Tumor Growth: The Role of Cancer Stem Cells in Drug Resistance and Recurrence
2022 · Beatrice Aramini, Valentina Masciale, et al. · Cancers · 147
PDF
First-line pembrolizumab in advanced non–small cell lung cancer patients with poor performance status
2020 · Francesco Facchinetti, Giulia Mazzaschi, et al. · European Journal of Cancer · 143
Baseline BMI and BMI variation during first line pembrolizumab in NSCLC patients with a PD-L1 expression ≥ 50%: a multicenter study with external validation
2020 · Alessio Cortellini, Biagio Ricciuti, et al. · Journal for ImmunoTherapy of Cancer · 103
PDF
Clinicopathologic correlates of first-line pembrolizumab effectiveness in patients with advanced NSCLC and a PD-L1 expression of ≥ 50%
2020 · Alessio Cortellini, Marcello Tiseo, et al. · Cancer Immunology Immunotherapy · 96
PDF
Molecular Mechanisms and Cellular Contribution from Lung Fibrosis to Lung Cancer Development
2021 · Anna Valeria Samarelli, Valentina Masciale, et al. · International Journal of Molecular Sciences · 92
PDF
Immune-related Adverse Events of Pembrolizumab in a Large Real-world Cohort of Patients With NSCLC With a PD-L1 Expression ≥ 50% and Their Relationship With Clinical Outcomes
2020 · Alessio Cortellini, Alex Friedlaender, et al. · Clinical Lung Cancer · 86
PDF
Resistance to Selective FGFR Inhibitors in FGFR- Driven Urothelial Cancer
2023 · Francesco Facchinetti, Antoine Hollebecque, et al. · Cancer Discovery · 79
Neoadjuvant treatments in triple-negative breast cancer patients: where we are now and where we are going
2018 · Claudia Omarini, Giorgia Guaitoli, et al. · Cancer Management and Research · 75
PDF
The lung immuno-oncology prognostic score (LIPS-3): a prognostic classification of patients receiving first-line pembrolizumab for PD-L1 ≥ 50% advanced non-small-cell lung cancer
2021 · G.L. Banna, A. Cortellini, et al. · ESMO Open · 62
PDF
Impact of time to surgery after neoadjuvant chemotherapy in operable breast cancer patients
2016 · C. Omarini, G. Guaitoli, et al. · European Journal of Surgical Oncology · 62
Impact of body composition, nutritional and inflammatory status on outcome of non-small cell lung cancer patients treated with immunotherapy
2021 · Cinzia Baldessari, Giorgia Guaitoli, et al. · Clinical Nutrition ESPEN · 42
Immune checkpoint inhibitors in oncogene-addicted non-small cell lung cancer: a systematic review and meta-analysis
2021 · Giorgia Guaitoli, Marcello Tiseo, et al. · Translational Lung Cancer Research · 38
PDF
Predictive ability of a drug-based score in patients with advanced non–small-cell lung cancer receiving first-line immunotherapy
2021 · Sebastiano Buti, Melissa Bersanelli, et al. · European Journal of Cancer · 35
Non-small-cell lung cancer: how to manage BRAF-mutated disease
2023 · Giorgia Guaitoli, Lodovica Zullo, et al. · Drugs in Context · 34
PDF
Detection of EGFR-Activating and T790M Mutations Using Liquid Biopsy in Patients With EGFR-Mutated Non–Small-Cell Lung Cancer Whose Disease Has Progressed During Treatment With First- and Second-Generation Tyrosine Kinase Inhibitors: A Multicenter Real-Life Retrospective Study
2020 · Roberta Minari, Giulia Mazzaschi, et al. · Clinical Lung Cancer · 31
Clinical and molecular predictors of long-term response in HER2 positive metastatic breast cancer patients
2018 · Claudia Omarini, Stefania Bettelli, et al. · Cancer Biology & Therapy · 29
PDF
Deepening the Knowledge of ROS1 Rearrangements in Non-Small Cell Lung Cancer: Diagnosis, Treatment, Resistance and Concomitant Alterations
2021 · Giorgia Guaitoli, Federica Bertolini, et al. · International Journal of Molecular Sciences · 23
PDF
INfluenza Vaccine Indication During therapy with Immune checkpoint inhibitors: a multicenter prospective observational study (INVIDIa-2)
2021 · Melissa Bersanelli, Diana Giannarelli, et al. · Journal for ImmunoTherapy of Cancer · 23
PDF
Efficacy and safety of Everolimus and Exemestane in hormone-receptor positive (HR+) human-epidermal-growth-factor negative (HER2−) advanced breast cancer patients: New insights beyond clinical trials. The EVA study
2017 · M.E. Cazzaniga, M. Airoldi, et al. · The Breast · 22
Impact of influenza vaccination on survival of patients with advanced cancer receiving immune checkpoint inhibitors (INVIDIa-2): final results of the multicentre, prospective, observational study
2023 · Melissa Bersanelli, Elena Verzoni, et al. · EClinicalMedicine · 20
PDF
Role of evaluating tumor‑infiltrating lymphocytes, programmed death‑1 ligand 1 and mismatch repair proteins expression in malignant mesothelioma
2019 · Lorena Losi, Federica Bertolini, et al. · International Journal of Oncology · 18
PDF
Multicenter Observational Study on Metastatic Non-Small Cell Lung Cancer Harboring BRAF Mutations: Focus on Clinical Characteristics and Treatment Outcome of V600E and Non-V600E Subgroups
2022 · Fabiana Perrone, Giulia Mazzaschi, et al. · Cancers · 17
PDF
Treating cancer with immunotherapy in HIV-positive patients: A challenging reality
2019 · Giorgia Guaitoli, Cinzia Baldessari, et al. · Critical Reviews in Oncology/Hematology · 16
Real-world outcomes of Italian patients with advanced non-squamous lung cancer treated with first-line pembrolizumab plus platinum-pemetrexed
2024 · Alessandro Leonetti, Fabiana Perrone, et al. · European Journal of Cancer · 14
PDF
Works count: 168
Citation count: 1,589
H-index: 20
I10-index: 30
Year
Topic
Type